Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Deseret News Utah Index
Deseret News Composite
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Petros Pharmaceuticals Inc
(NQ:
PTPI
)
0.3450
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
0.3450
Bid (Size)
0.3310 (4)
Ask (Size)
0.3785 (3)
Prev. Close
0.3450
Today's Range
0.3450 - 0.3450
52wk Range
0.3006 - 3.250
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
PTPI Stock Earnings: Petros Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
August 16, 2024
PTPI stock results show that Petros Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Petros Pharmaceuticals' Pivotal Statistically Significant Self Selection Study Shows Stronger Results with Proprietary Technology Application as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)
July 29, 2024
Via
ACCESSWIRE
Performance
YTD
-75.70%
-75.70%
1 Month
-19.77%
-19.77%
3 Month
-44.79%
-44.79%
6 Month
-77.88%
-77.88%
1 Year
-88.42%
-88.42%
More News
Read More
Petros Pharmaceuticals’ STENDRA(R) (avanafil) Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance
July 16, 2024
Via
ACCESSWIRE
EXCLUSIVE: 'Prescription Erectile Dysfunction Market Could Triple If an ED Therapy Is Made Available OTC,' Petros Pharma President Says
June 17, 2024
Via
Benzinga
Why Signet Jewelers Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
June 13, 2024
Via
Benzinga
Petros Pharmaceuticals Activates Advisory Committee to Help Guide Rx-to-OTC Switch for STENDRA
May 21, 2024
Via
ACCESSWIRE
12 Health Care Stocks Moving In Thursday's Intraday Session
June 13, 2024
Via
Benzinga
Why Broadcom Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
June 13, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
June 13, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
June 13, 2024
Via
InvestorPlace
Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA(R) (avanafil)
April 16, 2024
Via
ACCESSWIRE
12 Health Care Stocks Moving In Wednesday's After-Market Session
May 29, 2024
Via
Benzinga
Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA(R) (avanafil) OTC Switch
May 29, 2024
Via
ACCESSWIRE
PTPI Stock Earnings: Petros Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024
May 16, 2024
Via
InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
May 15, 2024
Via
Benzinga
Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals
May 14, 2024
From
23andMe, Inc.
Via
GlobeNewswire
Petros Pharmaceuticals Launches U.S. Distribution of Prescription ED Medication STENDRA Through Recently Announced Collaboration With Lemonaid Health, a Subsidiary of 23andMe
May 14, 2024
Via
ACCESSWIRE
Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA(R) (avanafil) Through New Agreement with Lemonaid Health
April 23, 2024
Via
ACCESSWIRE
Why Stryve Foods Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
April 02, 2024
Via
Benzinga
PTPI Stock Earnings: Petros Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023
April 02, 2024
Via
InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
April 02, 2024
Via
Benzinga
Petros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA(R) (avanafil) as it Pursues OTC Status
April 02, 2024
Via
ACCESSWIRE
Petros Pharmaceuticals Successfully Launches AI Tool In Collaboration with Multi-Billion-Dollar Software Provider
March 19, 2024
Via
ACCESSWIRE
BestGrowthStocks.Com Issues Comprehensive Analysis of Petros Pharmaceuticals Inc
March 11, 2024
Via
TheNewswire.com
Exposures
Product Safety
BestGrowthStocks.Com Issues Comprehensive Analysis of Petros Pharmaceuticals Inc
March 11, 2024
Via
News Direct
Exposures
Product Safety
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.